Patents by Inventor Matthew P. Pando

Matthew P. Pando has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
    Patent number: 9902710
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: October 16, 2015
    Date of Patent: February 27, 2018
    Assignees: EXONHIT THERAPEUTICS, SA, ALLERGAN, INC.
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
    Patent number: 9670181
    Abstract: The invention relates to compounds of the formula wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: June 6, 2017
    Assignees: ALLERGAN, INC., EXONHIT THERAPEUTICS SA
    Inventors: Bertrand Leblond, Cedric Chauvignac, Thierry Taverne, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
    Publication number: 20160264549
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: October 16, 2015
    Publication date: September 15, 2016
    Applicant: EXONHIT THERAPEUTICS, SA
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
    Patent number: 9200016
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: December 1, 2015
    Assignees: Allergan, Inc., Exonhit Therapeutics, SA
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
    Publication number: 20150158895
    Abstract: The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 11, 2015
    Applicant: Allergan, Inc.
    Inventors: Bertrand Leblond, Thierry Taverne, Cedric Chauvignac, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
    Publication number: 20140309253
    Abstract: The invention relates to compounds of the formula wherein R?, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: June 25, 2014
    Publication date: October 16, 2014
    Inventors: Bertrand Leblond, Cedric Chauvignac, Thierry Taverne, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Desire, Matthew P. Pando, John E. Donello, Rong Yang
  • Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (PDE10A)
    Patent number: 8772316
    Abstract: The invention relates to compounds of the formula wherein R?, R1, through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: July 8, 2014
    Assignees: Allergan, Inc., Exonhit Therapeutics SA
    Inventors: Bertrand Leblond, John E. Donello, Cédric Chauvignac, Thierry Taverne, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Désiré, Matthew P. Pando, Rong Yang
  • METHODS FOR TREATING DISEASES OF THE RETINA
    Publication number: 20120214842
    Abstract: Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of Formula I as defined herein. These compounds are useful as PDE10 inhibitors.
    Type: Application
    Filed: February 16, 2012
    Publication date: August 23, 2012
    Applicants: ExonHit Therapeutics SA, ALLERGAN, INC.
    Inventors: John E. Donello, Rong Yang, Bertrand Leblond, Eric Beausoleil, Matthew P. Pando, Laurent Désiré, Anne-Sophie Casagrande, Veena Viswanath
  • SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)
    Publication number: 20120214837
    Abstract: The invention relates to compounds of the formula wherein R?, R1, through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicants: ExonHit Therapeutics SA, ALLERGAN, INC.
    Inventors: Bertrand Leblond, Cédric Chauvignac, Thierry Taverne, Eric Beausoleil, Anne-Sophie Casagrande, Laurent Désiré, Matthew P. Pando, John E. Donello, Rong Yang
  • Prostate specific genes and the use thereof as targets for prostate cancer therapy
    Patent number: 7834163
    Abstract: Genes that are upregulated in human prostate tumor tissues and the corresponding proteins are identified. These genes and the corresponding antigens are suitable targets for the treatment, diagnosis or prophylaxis of prostate cancer.
    Type: Grant
    Filed: June 25, 2004
    Date of Patent: November 16, 2010
    Assignee: Exonhit Therapeutics S.A.
    Inventors: Richard Einstein, Kevin M. McGowan, Matthew P. Pando